Genialis Advances Biomarker Discovery to Reduce Risk in Cancer Drug Development Targeting DNA Damage Response Pathways
Genialis and Debiopharm expand collaboration to develop RNA-based predictive biomarkers for DDR therapies, advancing precision oncology.
Morningstar6d
Genialis Advances Biomarker Discovery to Reduce Risk in Cancer Drug Development Targeting DNA Damage Response Pathways
Most cancers cannot be adequately characterized by individual mutations or proteins, or even a composite of these,” said Rafael Rosengarten, Ph.D., CEO of Genialis. “The Genialis Supermodel is ...
Investing6d
Genialis, Debiopharm advance WEE1 therapy biomarker development
Rafael Rosengarten, Ph.D., CEO of Genialis, noted the critical need for predictive biomarkers in DDR therapy development. The Genialis Supermodel, which has been instrumental in their biomarker ...
Goethe5d
Grün ist die Farbe der Erinnerung
Weitere Sehenswürdigkeiten: der sogenannte Schweizer Uhrturm (Reloj Suizo, 1938), und das Denkmal für den Politiker Rafael Uribe Uribe ... mehreren Spielplätzen, einem Rosengarten, dem Sommerbad ...
Investing6d
Genialis und Debiopharm treiben Entwicklung von Biomarkern für WEE1-Therapie voran
Rafael Rosengarten, Ph.D., CEO von Genialis, unterstreicht den dringenden Bedarf an prädiktiven Biomarkern in der DDR-Therapieentwicklung. Das Genialis Supermodel, das bereits bei KRAS-gezielten ...